Business Context and Reporting Period
Company: Milestone Scientific Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Milestone develops and markets proprietary, computer-controlled injection technologies for the dental and medical markets. Key products include the STA Single Tooth Anesthesia Instrument, CompuDent, and CompuMed. The company relies on third-party contract manufacturers and a network of distributors globally.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Total Revenue | $9,749,968 | $8,549,060 |
| Gross Profit | $6,218,516 | $5,090,781 |
| Gross Margin | 64% | 60% |
| Net Loss | $(614,508) | $(1,530,085) |
| Cash and Cash Equivalents | $627,082 | $1,029,129 |
| Working Capital | $(6,685) | $1,626,073 |
| Accumulated Deficit | $(59,377,962) | $(58,763,454) |
| Long-Term Debt | $441,639 | $438,843 |
Note: Working capital turned negative in 2010 due to inventory buildup and receivables related to a delayed China shipment.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 14% to $9.75 million, driven primarily by a $1.29 million shipment of STA instruments to a Chinese distributor (Sinopharm) in June 2010.
- Domestic vs. International: Domestic sales decreased 16% to $4.53 million due to reduced advertising and sales force optimization. International sales increased 65% to $5.22 million.
- Profitability: Net loss improved by 60% to $614,508, aided by a 4% increase in gross profit dollars and a $304,000 reduction in selling, general, and administrative (SG&A) expenses.
- Liquidity Deterioration: Working capital shifted from positive $1.63 million in 2009 to negative $6,685 in 2010. This was caused by a $636,000 bad debt reserve against the China distributor receivable and increased advances to contract manufacturers ($2.44 million total) in anticipation of sales that were delayed pending regulatory approval.
- Other Income: Other income dropped significantly from $777,609 in 2009 to $183,673 in 2010, as the company sold all applicable New Jersey tax credits through 2009.
Guidance, Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that recurring losses and negative operating cash flows raise substantial doubt about the company's ability to continue as a going concern. Management believes cash reserves are insufficient to meet obligations for the next twelve months without additional capital.
- China Regulatory Delay: Shipments to the Chinese distributor (Sinopharm) are suspended pending regulatory approval, expected in 2011. This delay has resulted in a significant bad debt reserve and negative working capital.
- Capital Needs: The company may need to raise additional capital to fund marketing efforts or operations. Failure to do so could force curtailment of development activities or marketing expenses.
- Joint Venture: An Agreement of Intent was signed in late 2009 with Chinese partners to develop medical drug delivery instruments. As of March 2011, the agreement had not been finalized.
- Management Commentary: Management is focusing on optimizing sales strategies, expanding the distribution network, and reducing operating expenses to achieve positive cash flow.
Investor Verification Checklist
- China Regulatory Status: Verify the current status of the regulatory approval required by the Chinese government to release the suspended shipment of 12,000 STA instruments.
- Bad Debt Reserve: Assess the collectability of the $636,000 reserve taken against the China distributor receivable and the likelihood of future payments.
- Cash Runway: Confirm the company's ability to meet obligations for the next 12 months given the negative working capital and stated cash shortfall.
- Capital Raising: Monitor for any announcements regarding equity or debt financing to address liquidity constraints.
- Joint Venture Finalization: Track the progress of the joint venture agreement with China National Medicines Corporation and Yichang Humanwell Pharmaceutical Co. Ltd.